{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:38:22Z","timestamp":1793824702998,"version":"4.6.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI143965"],"award-info":[{"award-number":["AI143965"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.anai.2024.03.002","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T04:04:22Z","timestamp":1710389062000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Bruton's tyrosine kinase inhibition for the treatment of allergic disorders"],"prefix":"10.1016","volume":"133","author":[{"given":"Erica V.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragha V.","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6655-3279","authenticated-orcid":false,"given":"Melanie C.","family":"Dispenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2024.03.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106577","article-title":"Recent research of BTK inhibitors: methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship","volume":"138","author":"Wang","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.anai.2024.03.002_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton's tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2024.03.002_bib0003","doi-asserted-by":"crossref","unstructured":"Bernstein JA, Maurer M, Saini SS. BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria [e-pub ahead of print]. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2023.12.008, accessed January 9, 2024.","DOI":"10.1016\/j.jaci.2023.12.008"},{"issue":"5","key":"10.1016\/j.anai.2024.03.002_bib0004","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.jaci.2017.12.987","article-title":"Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy","volume":"141","author":"Dispenza","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"10.1016\/j.anai.2024.03.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172335","article-title":"A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.anai.2024.03.002_bib0006","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.03.002_bib0007","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.03.002_bib0008","series-title":"American College of Allergy, Asthma, and Immunology Annual Scientific Meeting","article-title":"Remibrutinib: results of the phase 3 REMIX-1 and REMIX-2 studies","author":"Saini","year":"2023"},{"issue":"11","key":"10.1016\/j.anai.2024.03.002_bib0009","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.anai.2024.03.002_bib0010","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.3390\/ijms25042208","article-title":"Bruton's tyrosine kinase inhibitors: recent updates","volume":"25","author":"Fares","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.anai.2024.03.002_bib0011","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.anai.2024.03.002_bib0012","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1091581820918511","article-title":"Nonclinical safety assessment of zanubrutinib: a novel irreversible BTK inhibitor","volume":"39","author":"Zhang","year":"2020","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.anai.2024.03.002_bib0013","doi-asserted-by":"crossref","unstructured":"De SK. Pirtobrutinib: first non-covalent tyrosine kinase inhibitor for treating relapsed or refractory mantle cell lymphoma in adults [e-pub ahead of print]. Curr Med Chem. https:\/\/doi.org\/10.2174\/0109298673251030231004052822, accessed January 9, 2024.","DOI":"10.2174\/0109298673251030231004052822"},{"issue":"18","key":"10.1016\/j.anai.2024.03.002_bib0014","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib versus Ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia:the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.anai.2024.03.002_bib0015","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.anai.2024.03.002_bib0016","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1080\/10428194.2023.2254876","article-title":"Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes","volume":"64","author":"Redd","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.anai.2024.03.002_bib0017","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton's tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.anai.2024.03.002_bib0018","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/cts.13005","article-title":"Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial","volume":"14","author":"Kaul","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.anai.2024.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/cts.13524","article-title":"Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: absorption, metabolism, excretion, and absolute bioavailability in healthy participants","volume":"16","author":"Ucpinar","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.anai.2024.03.002_bib0020","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.03.002_bib0021","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.intimp.2010.12.018","article-title":"Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor","volume":"11","author":"MacGlashan","year":"2011","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.anai.2024.03.002_bib0023","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.anai.2024.03.002_bib0024","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/all.13166","article-title":"BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils","volume":"72","author":"Smiljkovic","year":"2017","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2024.03.002_bib0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/jamp.2015.1210","article-title":"Btk inhibitor RN983 delivered by dry powder nose-only aerosol inhalation inhibits bronchoconstriction and pulmonary inflammation in the ovalbumin allergic mouse model of asthma","volume":"29","author":"Phillips","year":"2016","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"Pt 2","key":"10.1016\/j.anai.2024.03.002_bib0026","first-page":"225","article-title":"Production and life span of cutaneous mast cells in young rats","volume":"128","author":"Kiernan","year":"1979","journal-title":"J Anat"},{"issue":"3","key":"10.1016\/j.anai.2024.03.002_bib0027","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2017.03.013","article-title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity","volume":"140","author":"Regan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.03.002_bib0028","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.03.002_bib0029","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jaci.2012.10.017","article-title":"Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report","volume":"130","author":"Sampson","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.03.002_bib0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.18176\/jiaci.0143","article-title":"Oral immunotherapy for food allergy","volume":"27","author":"Wood","year":"2017","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.03.002_bib0031","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/all.14220","article-title":"Food allergy immunotherapy: oral immunotherapy and epicutaneous immunotherapy","volume":"75","author":"Kim","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0032","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.iac.2019.09.013","article-title":"Safety of food oral immunotherapy: what we know, and what we need to learn","volume":"40","author":"Vazquez-Cort\u00e9s","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"10.1016\/j.anai.2024.03.002_bib0033","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/pai.12767","article-title":"Combining anti-IgE with oral immunotherapy","volume":"28","author":"Lin","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0034","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.iac.2019.09.004","article-title":"Food allergy immunotherapy with adjuvants","volume":"40","author":"Nicolaides","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.anai.2024.03.002_bib0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/all.13319","article-title":"EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy","volume":"73","author":"Pajno","year":"2018","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.anai.2024.03.002_bib0036","doi-asserted-by":"crossref","first-page":"771.e1","DOI":"10.1016\/j.jtct.2022.08.021","article-title":"Ibrutinib treatment of pediatric chronic graft-versus-host disease: primary results from the Phase 1\/2 iMAGINE study","volume":"28","author":"Carpenter","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.anai.2024.03.002_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100640","article-title":"Standards for practical intravenous rapid drug desensitization & delabeling: a WAO committee statement","volume":"15","author":"Alvarez-Cuesta","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"2","key":"10.1016\/j.anai.2024.03.002_bib0038","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jaip.2022.10.017","article-title":"Pretreatment with ibrutinib facilitates rapid drug desensitization in a difficult case of brentuximab vedotin-induced anaphylaxis","volume":"11","author":"Rodsaward","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0039","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaip.2018.06.030","article-title":"Controversies in drug allergy: radiographic contrast media","volume":"7","author":"S\u00e1nchez-Borges","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2024.03.002_bib0041","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"7542","key":"10.1016\/j.anai.2024.03.002_bib0042","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.anai.2024.03.002_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676354","article-title":"MRGPRX2 and adverse drug reactions","volume":"12","author":"McNeil","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.anai.2024.03.002_bib0044","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/all.15261","article-title":"Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"77","author":"Mendes-Bastos","year":"2022","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.anai.2024.03.002_bib0045","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.jaip.2023.02.022","article-title":"Chronic spontaneous urticaria: the role and relevance of autoreactivity, autoimmunity, and autoallergy","volume":"11","author":"Asero","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2024.03.002_bib0046","doi-asserted-by":"crossref","first-page":"e12227","DOI":"10.1002\/clt2.12227","article-title":"Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of Fc\u03b5R1 expression level and omalizumab clinical response","volume":"13","author":"Gimeno","year":"2023","journal-title":"Clin Transl Allergy"},{"issue":"10","key":"10.1016\/j.anai.2024.03.002_bib0047","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a Phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.anai.2024.03.002_bib0048","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES Study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.anai.2024.03.002_bib0049","series-title":"American Academy of Allergy, Asthma, & Immunology Annual Scientific Meeting","article-title":"Efficacy and safety of rilzabrutinib in patients with chronic spontaneous urticaria: 12-week results from the RILECSU Phase 2 dose-ranging study","author":"Maurer","year":"2024"},{"issue":"15","key":"10.1016\/j.anai.2024.03.002_bib0050","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.anai.2024.03.002_bib0051","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/jcm11102807","article-title":"Bruton's kinase inhibitors for the treatment of immunological diseases: current status and perspectives","volume":"11","author":"Robak","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.anai.2024.03.002_bib0052","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4049\/immunohorizons.2100063","article-title":"Preclinical mechanisms of topical PRN473, a Bruton tyrosine kinase inhibitor. in immune-mediated skin disease models","volume":"5","author":"Xing","year":"2021","journal-title":"Immunohorizons"},{"key":"10.1016\/j.anai.2024.03.002_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104441","volume":"148","author":"Nadeem","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.anai.2024.03.002_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109920","article-title":"Bruton's tyrosine kinase inhibition suppresses neutrophilic inflammation and restores histone deacetylase 2 expression in myeloid and structural cells in a mixed granulocytic mouse model of asthma","volume":"117","author":"Nadeem","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp-2022-328799","article-title":"Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis","volume":"94","author":"Montalban","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.anai.2024.03.002_bib0056","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2017.07.008","article-title":"X-linked agammaglobulinaemia: outcomes in the modern era","volume":"183","author":"Shillitoe","year":"2017","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.03.002_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2019.100018","article-title":"X-linked agammaglobulinemia (XLA):phenotype, diagnosis, and therapeutic challenges around the world","volume":"12","author":"El-Sayed","year":"2019","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.anai.2024.03.002_bib0058","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.anai.2024.03.002_bib0059","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton tyrosine kinase inhibitors: present and future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.anai.2024.03.002_bib0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-019-00635-7","article-title":"Inhibiting Bruton's tyrosine kinase in CLL and other B-cell malignancies","volume":"14","author":"Lucas","year":"2019","journal-title":"Target Oncol"},{"issue":"5","key":"10.1016\/j.anai.2024.03.002_bib0061","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1177\/1078155220915956","article-title":"The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma","volume":"26","author":"Hanna","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"10.1016\/j.anai.2024.03.002_bib0062","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11886-023-01916-4","article-title":"Diagnosis and management of cardiovascular effects of bruton's tyrosine kinase inhibitors","volume":"25","author":"Aghel","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"10.1016\/j.anai.2024.03.002_bib0063","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease","volume":"13","author":"von Hundelshausen","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0064","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10840-023-01575-z","article-title":"Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors","volume":"67","author":"Wei","year":"2024","journal-title":"J Interv Card Electrophysiol"},{"issue":"5","key":"10.1016\/j.anai.2024.03.002_bib0065","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"19","key":"10.1016\/j.anai.2024.03.002_bib0066","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.anai.2024.03.002_bib0067","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1080\/10428194.2020.1772477","article-title":"Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors","volume":"61","author":"Pleyer","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.anai.2024.03.002_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.anai.2024.03.002_bib0069","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.anai.2024.03.002_bib0070","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1080\/10428194.2023.2258243","article-title":"Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL","volume":"64","author":"Tomasulo","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"11-12","key":"10.1016\/j.anai.2024.03.002_bib0071","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1177\/13524585231192460","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: a Bruton's tyrosine kinase inhibitor","volume":"29","author":"Bar-Or","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.anai.2024.03.002_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.anai.2024.03.002_bib0073","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/ajhp\/zxad210","article-title":"Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies","volume":"81","author":"Tham","year":"2024","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0074","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.anai.2024.03.002_bib0075","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1080\/10428194.2020.1775215","article-title":"Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"61","author":"Frei","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.anai.2024.03.002_bib0076","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.anai.2024.03.002_bib0077","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.anai.2024.03.002_bib0078","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clml.2023.04.006","article-title":"Hepatitis B virus reactivation in patients receiving Bruton tyrosine kinase inhibitors","volume":"23","author":"Chiu","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0079","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41392-022-01249-8","article-title":"Small molecules in the treatment of COVID-19","volume":"7","author":"Lei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"10.1016\/j.anai.2024.03.002_bib0080","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"issue":"48","key":"10.1016\/j.anai.2024.03.002_bib0081","doi-asserted-by":"crossref","first-page":"eabd0110","DOI":"10.1126\/sciimmunol.abd0110","article-title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19","volume":"5","author":"Roschewski","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.03.002_bib0082","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-020-00999-8","article-title":"Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer","volume":"14","author":"Benner","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.anai.2024.03.002_bib0083","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarfo","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.anai.2024.03.002_bib0084","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.anai.2024.03.002_bib0085","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/vco.12520","article-title":"Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells","volume":"17","author":"Gamperl","year":"2019","journal-title":"Vet Comp Oncol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T16:17:05Z","timestamp":1731946625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1081120624001455"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.03.002","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bruton's tyrosine kinase inhibition for the treatment of allergic disorders","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. All rights reserved.","name":"copyright","label":"Copyright"}]}}